Understanding why some patients have heart damage from doxorubicin and how to predict it
Official title: Role of oxidative stress in doxorubicin-induced cardiotoxicity
Funded at Louisiana State Univ Hsc Shreveport · NIH-11379116 · Data updated 2026-11-12
This grant looks at why doxorubicin can damage the heart in some patients and how genetic differences, especially related to oxidative stress, might help predict who is at higher risk.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louisiana State Univ Hsc Shreveport NIH-funded |
| Lab location | 1 site (Shreveport, United States) |
| Project start | February 1, 2018 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $196,583 |
| NIH project number | 5P20GM121307-09 |
| Project ID | NIH-11379116 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients receiving doxorubicin, especially those with genetic backgrounds suggesting higher oxidative stress or EPHA2-AS1-related risk.
✕Less likely to help
Patients without the identified risk profiles or those not treated with doxorubicin may see no direct benefit.
What this research studies
Doxorubicin is a common chemotherapy with a known risk of heart damage that varies between people. The project studies how a patient’s genetic makeup affects oxidative stress and heart cell vulnerability to doxorubicin. Researchers propose that a newly identified genetic locus near EPHA2-AS1 may influence this risk by altering oxidative stress pathways in heart cells derived from patients. The work connects genetics, cellular models, and heart health to better understand who might be most at risk in order to guide future care. Results could lead to personalized strategies to prevent or mitigate cardiotoxicity during cancer treatment.
Why it matters
Potential benefit: Better prediction of who is at risk for doxorubicin-related heart damage and development of personalized strategies to protect the heart during chemotherapy.
How similar studies have gone: Previous work supports a link between oxidative stress and doxorubicin cardiotoxicity, with ongoing efforts to tailor risk based on genetics.
Where this research is happening
-
Louisiana State Univ Hsc Shreveport
Shreveport, United States Active
Researchers
- Principal investigator: Mohamed, Tarek Magdy — Louisiana State Univ Hsc Shreveport
- Study coordinator: Mohamed, Tarek Magdy
Related research
Other NIH-funded projects on the same topics.
-
Understanding Heart Damage from Doxorubicin Chemotherapy
This research explores why some patients experience heart damage from doxorubicin chemotherapy while others don't, focusing on individual genetic differences.
-
Investigating how oxidative stress affects heart damage from doxorubicin in different racial groups
This study is looking into why African Americans may have more heart problems from the cancer drug doxorubicin than White Americans, by exploring how a specific gene and oxidative stress affect heart cells, using samples from both groups to find out what makes their responses different.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
How vitamin B12 helps the gum-disease bacterium survive
Learning how vitamin B12 helps the bacteria that cause gum disease survive and become more harmful for people with periodontitis.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.